Edition:
United States

MyoKardia Inc (MYOK.OQ)

MYOK.OQ on NASDAQ Stock Exchange Global Select Market

50.10USD
2:19pm EDT
Change (% chg)

$0.30 (+0.60%)
Prev Close
$49.80
Open
$50.20
Day's High
$50.65
Day's Low
$49.30
Volume
27,952
Avg. Vol
126,634
52-wk High
$62.70
52-wk Low
$12.20

Chart for

About

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializi... (more)

Overall

Beta: --
Market Cap(Mil.): $1,798.60
Shares Outstanding(Mil.): 35.94
Dividend: --
Yield (%): --

Financials

  MYOK.OQ Industry Sector
P/E (TTM): -- 173.69 32.21
EPS (TTM): -1.41 -- --
ROI: -22.40 -0.70 13.05
ROE: -23.74 -2.69 14.90

BRIEF-MyoKardia Begins Dosing In Phase 2 MAVERICK-HCM Clinical Trial Of Mavacamten

* HCM TRIAL ARE ANTICIPATED IN SECOND HALF OF 2019 Source text for Eikon: Further company coverage:

Apr 02 2018

BRIEF-Myokardia Files For Potential Mixed Shelf Offering

* MYOKARDIA INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2FCACNv) Further company coverage:

Mar 08 2018

BRIEF-Myokardia Reports Q4 Loss Per Share Of $0.21

* MYOKARDIA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 08 2018

BRIEF-Myokardia Begins Patient Dosing In Phase 1B Clinical Study Of Myk-491

* MYOKARDIA BEGINS PATIENT DOSING IN PHASE 1B CLINICAL STUDY OF MYK-491 IN DILATED CARDIOMYOPATHY PATIENTS

Feb 14 2018

BRIEF-MyoKardia Inc reports Q3 loss per share $0.42

* MyoKardia Inc reports third quarter 2017 financial results and operational progress

Nov 02 2017

Earnings vs. Estimates